ロード中...
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
PURPOSE: Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS: Fifty-nine adult patients (age 42 to 82 years) with...
保存先:
| 出版年: | J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4878047/ https://ncbi.nlm.nih.gov/pubmed/23270003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.8623 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|